Frank Comer

Company: AstraZeneca

Job title: Director, Tumor Targeted Delivery, Early Oncology Discovery

Seminars:

Fireside: Paving the Path for Novel Radiopharmaceutical Targets or Following Bonified ADC Targets: Advantages & Pitfalls 1:30 pm

Leveraging established ADC Targets for radiopharmaceuticals for well characterized mechanism of action such as NECTIN-4 Identifying and pursuing untapped biological targets to revolutionize radiopharmaceuticals such as failed ADC targets Commercial considerations to balance risks and hurdlesRead more

day: Conference Day One

Creating the ‘Ideal’ Radiopharmaceutical: Considerations for the Drug Design Toolbox 9:02 am

Delve into a holistic overview of the art of novel radiopharmaceutical drug design. With cutting-edge progress expanding the tools used in novel radiopharmaceutical drug development there is a great number of options to optimize the chemistry of your molecule. From targeting moiety, linker, chelator and payload – what are the considerations when approaching drug design…Read more

day: Pre-Conference Workshop Day

Panel Discussion: Investigating Attributes of a Prime Radiopharmaceutical Target to Match the Properties of a Radioactive Drug 9:00 am

Considering receptor density, expression levels and radiosensitive tissues Analyzing alpha vs beta emitter target requirements for optimal strategy Assessing stromal targeting such as FAP or internalized targetsRead more

day: Conference Day One